Lamivudine Milpharm

Lamivudine, the active ingredient in Lamivudine Milpharm, is a nucleoside reverse transcriptase inhibitor presented as a tablet for oral use. It treats HIV‑1 infection and chronic hepatitis B infection in adults. GNH USA supplies Lamivudine Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is used in the management of viral infections that rely on reverse transcription. - HIV‑1 infection: suppresses viral replication and improves immune function. - Chronic hepatitis B infection: reduces viral load and slows liver disease progression. - Prevention of mother‑to‑child transmission of HIV: lowers the risk of vertical transmission when combined with other antiretrovirals.

Lamivudine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Fatigue: generalized tiredness without specific cause. - Diarrhoea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Lactic acidosis: metabolic disturbance requiring immediate medical attention. - Severe hepatotoxicity: marked elevation of liver enzymes or liver failure, especially in patients with pre‑existing liver disease.

Before prescribing Lamivudine, clinicians should consider several safety aspects. - Renal function: adjust dose in patients with impaired clearance. - Hepatic disease: monitor liver enzymes regularly. - Co‑infection: assess for hepatitis C or other viral infections. - Pregnancy: weigh potential benefits against unknown risks. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Lamivudine can affect, and be affected by, other medicines.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis and mitochondrial toxicity. - Stavudine: heightened potential for peripheral neuropathy and lactic acidosis.

Moderate Interactions (Monitor Closely): - Rifampicin: may reduce lamivudine plasma concentrations. - Antacids containing aluminium or magnesium: can lower absorption if taken simultaneously. - Concomitant use of other nucleoside analogues: monitor for additive mitochondrial toxicity.